A randomized trial of botulinum toxin A for treatment of drooling

The authors compared the efficacy of three different doses ( 18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A ( BTX- A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea ( n = 32) using a single- center, prospective, double- blind, placebo- controlled dose- finding study. The primary endpoint was achieved with 75 MU BTX- A without treatment- related adverse events, suggesting BTX- A is a safe and effective treatment for patients with sialorrhea.